A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET)
Latest Information Update: 04 Dec 2024
At a glance
- Drugs Lu-177 octreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms KinLET
- Sponsors ITM Solucin
Most Recent Events
- 02 Dec 2024 Planned initiation date changed from 1 Sep 2024 to 1 Jan 2025.
- 24 Sep 2024 Planned initiation date changed from 1 Jun 2024 to 1 Sep 2024.
- 17 Sep 2024 Trial design presented at the 49th European Society for Medical Oncology Congress